Trastuzumab biosimilar(Protheragen)

N/A

Report date: 2025/03/07 17:34:29

Base Information

Drug NameTrastuzumab biosimilar(Protheragen)

Drug Alias NamePro-S06

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesProtheragen Inc

China Registration ClassN/A

Active CompaniesProtheragen Inc

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

ATC CodeN/A